Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib Plus Binimetinib and Pembrolizumab in BRAF V600 Mutant Melanoma
NCT02902042Phase 2Completed
- Start
- Apr 2018
- Primary completion
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in melanoma (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 42 days, Progression-free survival at 24 months and 1 more. Started Apr 2018; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02902042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02902042.